Mitogen-activated protein kinases (MAPKs) are the cell's conserved signaling relays: three-tier kinase cascades — MAPKKK → MAPKK → MAPK — in which each activated layer phosphorylates the next, turning a surface-receptor signal into a transcriptional decision within minutes. The family's four named routes are ERK (growth-factor response, see ERK), JNK (stress and apoptosis, see JNK), p38 (inflammation and cytokines, see p38), and ERK5. The cascades' combinatorial wiring — dozens of components shared across tiers — is how one kinase superfamily serves proliferation, differentiation, stress, and immunity at once.
All MAPKs share the two-lobed kinase fold with a activation-loop Thr-X-Tyr motif whose dual phosphorylation by the MAPKK swings the loop into the catalytic conformation — the 100%-conserved switch of the family.
A common docking groove (the D-site receptor) binds the "D-domain" of partners, giving specificity that the catalytic site alone could not.
Scaffold proteins (KSR for ERK, JIP for JNK) hold cascade tiers together, insulating parallel routes that share components.
Function
Growth: RAS→RAF→MEK→ERK is the canonical route from growth-factor receptors through RAS to cell-cycle entry — the pathway mutated into overdrive in perhaps a third of cancers.
Stress and inflammation: UV, osmotic shock, cytokines, and endotoxin activate JNK and p38, which phosphorylate c-Jun and ATF2 to reprogram transcription toward repair, senescence, or death.
Signaling logic: the three-tier amplification plus scaffolds and docking grooves make the cascade both sensitive and specific — a module biology reuses dozens of times per cell.
Regulation
Dual-specificity MAPKKs (MEK1/2, MKK3/6, MKK4/7) are the only activators; MAP-kinase phosphatases (DUSPs) strip both phosphates to shut the signal off — duration here decides outcome (proliferation versus differentiation).
Feedback from ERK onto SOS and RAF limits cascade gain — the loops targeted to delay resistance in melanoma therapy.
p38 is activated by MKK3/6 and shapes cytokine production in macrophages — the inflammatory arm immunity tunes.
Interactions
With PI3K-AKT it shares receptor inputs and cross-regulates outputs — growth signaling's two channels.
Downstream transcription factors (Elk-1, c-Jun/ATF2, Myc) convert phospho-signals into the immediate-early gene program of the nucleus.
RAF-MEK-ERK inhibitors (BRAF V600E drugs, MEK inhibitors) are the clinical exploitation of the cascade's linearity — melanoma and NSCLC mainstays.
Clinical Relevance
Oncology: RAS/RAF/MEK/ERK dysregulation spans most solid tumors; vemurafenib/dabrafenib (BRAF) plus trametinib (MEK) pair blockade with resistance management.
Inflammation: p38 inhibitors have been tried across rheumatoid arthritis and COPD — efficacy real, toxicity limiting; JNK in diabetes's beta-cell stress.
Basic science: the MAPK cascade is the textbook kinase cascade — the module that taught signaling biology its grammar.